Related Experiment Video
Updated: Nov 4, 2025
07:09
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
2.1K
Emerging Pharmacologic Therapies for Heart Failure With Reduced Ejection Fraction
Ammar G Chaudhary1, Fadi M Alreefi1, Mohammad A Aziz1
1Cardiovascular Diseases Department, King Faisal Specialist Hospital and Research Centre (Gen. Org.), Jeddah, Saudi Arabia.
CJC Open
|May 24, 2021
Summary
New heart failure medications, including sodium glucose cotransporter 2 inhibitors, vericiguat, and omecamtiv mecarbil, offer hope for reducing risks in patients with reduced ejection fraction heart failure.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Heart failure represents a significant global health challenge with substantial economic impact.
- Reduced ejection fraction heart failure carries a high residual risk despite existing therapies.
Purpose of the Study:
- To review emerging pharmacotherapies for heart failure with reduced ejection fraction.
- To discuss the potential impact of novel agents on current and future heart failure management.
Main Methods:
- Literature review of recent scientific publications and clinical trial data.
- Synthesis of knowledge regarding sodium glucose cotransporter 2 inhibitors, vericiguat, and omecamtiv mecarbil.
Main Results:
- Sodium glucose cotransporter 2 inhibitors, vericiguat, and omecamtiv mecarbil demonstrate promise in mitigating residual risk.
- A substantial body of evidence has rapidly emerged for these novel agents.
Conclusions:
- These novel agents are poised to influence heart failure pharmacotherapy trends and clinical recommendations.
- Future management of heart failure with reduced ejection fraction will likely incorporate these new treatment options.
Related Concept Videos
01:30Heart Failure V: Medical Management
63
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
63
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
640
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
640
01:22Heart Failure VI: Adjunct Therapies
69
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
69
01:22Heart Failure Drugs: Diuretics
582
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
582
01:22Heart Failure Drugs: β-Blockers
539
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
539
01:26Heart Failure Drugs: Inotropic Agents
901
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
901